When was Biofortuna founded?

Biofortuna was founded in 2008 and raised its 1st funding round 2 years after it was founded.

Where is Biofortuna located?

Biofortuna is headquartered in Birkenhead, United Kingdom.

How many employees does Biofortuna have?

As of Jul 31, 2026, the latest employee count at Biofortuna is 32.

Is Biofortuna a funded company?

Biofortuna is a funded company, having raised a total of $21.6M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 11, 2010.

How much is Biofortuna worth?

The latest valuation of Biofortuna is $***** as of Jul 18, 2017.

When was the latest funding round of Biofortuna?

Biofortuna's latest funding was a $***** Grant (prize money) round on Feb 20, 2026, with participation from 1 investor.

What is the annual revenue of Biofortuna?

Annual revenue of Biofortuna is between £1M and £10M as on Mar 31, 2017

Where does Biofortuna rank among its competitors?

Biofortuna ranks 6th amongst 370 active competitors, of which 41 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Biofortuna, which secured $303K in Feb, 2026.

Who are the top competitors of Biofortuna?

Biofortuna's top competitors include Novartis, Catalent and Biotage. Among them, Biofortuna secured the most recent funding round in February, 2026.

Biofortuna - 2026 Company Profile, Team, Funding & Competitors

Biofortuna is a series A company based in Birkenhead (United Kingdom), founded in 2008 by Nanette Douglas, Rachel Douglas and Katherine Douglas. It operates as a Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services. Biofortuna has raised $21.6M in funding, with a current valuation of $*****. The company has 370 active competitors, including 41 funded and 53 that have exited. Its top competitors include companies like Novartis, Catalent and Biotage.

Company Details

Website: www.biofortuna.com/
Social
Email ID: *****@biofortuna.com
Phone Number: +44 **********

Key Metrics

Founded Year

2008

Location

Birkenhead, United Kingdom

Stage

Series A

Total Funding

$21.6M in 9 rounds

Latest Funding Round

Grant (prize money), Feb 20, 2026, $*****

Post Money Valuation

$***** as on Jul 18, 2017

Investors

Gov Wales & 13 more

Ranked

6^th among 370 active competitors

Annual Revenue

£1M - £10M as on Mar 31, 2017

Employee Count

32 as on Jul 31, 2026

Investment & Acquisitions

Cryoniss

Similar Companies

Novartis & 422 more

View Biofortuna's full profile

Biofortuna is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIOFORTUNA LTD CIN: 6514391 , United Kingdom, Active	Feb 26, 2008	£1M - £10M (As on Mar 31, 2017)	-

Biofortuna has raised a total funding of $21.6M over 9 rounds. Its first funding round was on May 11, 2010. Its latest funding round was a Grant (prize money) round on Feb 20, 2026 for $*****. 1 investor participated in its latest round. Biofortuna has 6 institutional investors and 8 angel investors.

Here is the list of recent funding rounds of Biofortuna:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 20, 2026	6527902	Grant (prize money)	3353250	8377404	6367631	3532492
Mar 31, 2021	5863091	Series A	6835446	9877553	4153632	1089396
Aug 15, 2018	6810373	Series A	6016853	2335878	9437181	4445133

Access funding benchmarks and valuations. Sign up today!

View details of Biofortuna's funding rounds and investors

The founders of Biofortuna are Nanette Douglas, Rachel Douglas and Katherine Douglas.

Here are the details of Biofortuna's key team members:

Nanette Douglas: Co-Founder of Biofortuna.
Rachel Douglas: Co-Founder of Biofortuna.
Katherine Douglas: Co-Founder of Biofortuna.
Nick Ash: CEO of Biofortuna. They serve on the board of 1 company.
Contact Info: 2 email addresses

Biofortuna's Board of Directors

Biofortuna's board has 4 active members. Nick Ash is part of team and David Turner, Nicholas Ivor Leaves and Mark Hurley are independent board members.

Here is the list of Biofortuna's board of directors:

Name	Type	Representing	Status	Duration
{pgbwem	Team	-	Current	1y 1m
prkhsuy	Team	-	Past	5y 2m
tev{zaa	Investor	-	Past	3y 1m
David Turner	Independent board member	-	Current	7y 5m
tlepkew	Independent board member	-	Current	6y 6m
pjxzcna	Independent board member	-	Current	8y 8m
vt{dhof	Independent board member	-	Past	4y 3m
ndswqiz	Independent board member	-	Past	4y 9m
ri{yftl	Independent board member	-	Past	6y 8m
nrksdad	Independent board member	-	Past	4y 2m
fvp{qkv	Independent board member	-	Past	6y 5m
jrwggan	Independent board member	-	Past	4y 1m

View details of Biofortuna's Founder profiles and Board Members

Biofortuna's employee count trend

Biofortuna has 32 employees as of Jul 26. Here is Biofortuna's employee count trend over the years:

Uncover Biofortuna's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biofortuna include Novartis, Catalent and Biotage. Here is the list of Top 10 competitors of Biofortuna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, Genstar Capital & 4 others	68/100
3rd	Biotage 1989, Uppsala (Sweden), Acquired	Organic synthesis, analytical, and peptide chemistry services for drug discovery and development	-	Taaleri, Investor Growth Capital & 4 others	63/100
4th	Surrozen 2016, San Francisco (United States), Public	Pioneering targeted regenerative antibodies to repair tissue and restore organ function	$133M	The Column Group, Horizons Ventures & 13 others	59/100
5th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	56/100
6th	Biofortuna 2008, Birkenhead (United Kingdom), Series A	Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services	$21.6M	Gov Wales, Catapult Ventures & 12 others	55/100
7th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	Cencora, Alabama Launchpad & 7 others	55/100
8th	Stelis Biosource 2012, Bengaluru (India), Series C	CDMO providing solutions for end-to-end biopharmaceutical manufacturing needs	$195M	TPG, Think Investments & 3 others	53/100
9th	AmplifyBio 2021, Hilliard (United States), Deadpooled	Provider of contract research, development, and manufacturing services for biologic drugs	$230M	Hercules Capital, Casdin Capital	53/100
10th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100